| FKBP1A |
|---|
| Full Name | FKBP Prolyl Isomerase 1A |
| Symbol | FKBP1A (FKBP12) |
| Chromosomal Location | 20p13 |
| NCBI Gene ID | [2280](https://www.ncbi.nlm.nih.gov/gene/2280) |
| OMIM | [186945](https://www.omim.org/entry/186945) |
| Ensembl ID | ENSG00000107164 |
| UniProt ID | [P62942](https://www.uniprot.org/uniprot/P62942) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease) |
FKBP1A (FK506-binding protein 1A, also known as FKBP12) encodes a peptidyl-prolyl cis-trans isomerase (PPI) that catalyzes the isomerization of peptide bonds preceding proline residues. This 108-amino acid immunophilin protein is widely expressed throughout the body and brain, where it plays critical roles in protein folding, signal transduction, and cellular homeostasis. FKBP1A has been extensively studied for its role in immunosuppression through its interaction with the drug rapamycin and as a modulator of neuronal signaling pathways relevant to neurodegenerative diseases.
FKBP1A encodes a member of the FK506-binding protein family of peptidyl-prolyl cis-trans isomerases (PPIases). The protein is localized to the cytoplasm and performs several key cellular functions:
¶ Protein Folding and Catalysis
- PPIase activity: Catalyzes the cis-trans isomerization of peptide bonds preceding proline residues, accelerating protein folding
- Chaperone function: Assists in proper protein folding and prevents aggregation of misfolded proteins
- Complex formation: Binds to immunosuppressive drugs including cyclosporine A (CsA) and rapamycin (sirolimus)
- mTOR signaling: The FKBP12-rapamycin complex directly inhibits mTORC1 (mechanistic target of rapamycin complex 1), a central regulator of cell growth, autophagy, and protein synthesis
- Ryanodine receptor modulation: Interacts with ryanodine receptors (RyR) to modulate calcium release from the endoplasmic reticulum
- Ion channel regulation: Modulates various ion channels including the IP3 receptor and calcium release channels
- Synaptic plasticity: Involved in the regulation of NMDA receptor trafficking and synaptic signaling
- Tau pathology: May influence tau phosphorylation through indirect effects on kinases and phosphatases
- Autophagy regulation: Through mTOR inhibition, FKBP12 can promote autophagy, a critical process for clearing protein aggregates
FKBP1A has been implicated in Alzheimer's disease through several mechanisms:
- Tau pathology: FKBP12 may interact with tau phosphorylation pathways; increased PPIase activity has been reported in AD brain
- mTOR dysregulation: mTOR hyperactivation is a hallmark of AD; FKBP12/rapamycin can modulate this pathway
- Protein homeostasis: The protein folding and autophagy functions are relevant to AD pathogenesis
- Therapeutic targeting: Rapamycin (an FKBP12 ligand) has been explored for AD treatment due to its mTOR-inhibiting properties
In Parkinson's disease, FKBP1A has been studied for its role in:
- Alpha-synuclein aggregation: Autophagy induction through mTOR inhibition may help clear alpha-synuclein aggregates
- Neuroprotection: FKBP12 overexpression has shown neuroprotective effects in PD models
- LRRK2 interaction: Potential interactions with LRRK2 (leucine-rich repeat kinase 2), a major PD gene
- Huntington's disease: mTOR modulation via FKBP12 is relevant to Huntington's pathogenesis
- Amyotrophic lateral sclerosis (ALS): Autophagy induction pathways may be therapeutic targets
- Neurodevelopmental disorders: FKBP1A variants have been associated with neurodevelopmental conditions
FKBP1A is ubiquitously expressed with high levels in:
- Brain (cerebral cortex, hippocampus, cerebellum)
- Immune system (T-cells, B-cells)
- Heart and skeletal muscle
- Liver and kidney
In the brain, FKBP1A is expressed in neurons and glia, with particularly high expression in regions involved in learning and memory.
¶ Rapamycin and Analogs
- mTOR inhibition: The FKBP12-rapamycin complex is used clinically as an immunosuppressant and anticancer agent
- Neurodegeneration: Rapamycin has been tested in animal models of AD, PD, and Huntington's disease
- Analogs (rapalogs): Everolimus and temsirolimus have better brain penetration and are being explored for neurodegenerative diseases
- Small molecule inhibitors: FKBP12 PPIase inhibitors are being developed for various applications
- Neuroprotective compounds: Some FKBP ligands show promise for neuroprotection